Le Lézard
Classified in: Health, Business
Subject: CXP

Mission, TX's First Outpatient Cath Lab Opens


MISSION, Texas, Jan. 29, 2020 /PRNewswire/ -- The city of Mission, Texas, is getting its first outpatient catheterization lab, bringing a new level of convenience, cost savings, and state-of-the-art medical care to the area.

Arise Logo (PRNewsfoto/Arise Vascular)

Dr. Mego, a local Interventional Cardiologist, teamed up with Austin, Texas-based Arise Vascular to open the Mission Vascular Center of Excellence. Dr. Mego's program focuses on the treatment of Peripheral Artery Disease, also known as P.A.D. The facility is conveniently located at 1317 St. Claire Blvd. Suite A-5 Mission, TX 78572.

P.A.D. is a condition whereby the arteries in the legs become blocked and blood cannot flow properly into the legs and feet. One in 20 Americans over the age of 50 has P.A.D. People with diabetes, high cholesterol, kidney disease, obesity, high blood pressure, smoking, or coronary artery disease are all at increased risk of developing P.A.D.

Although it is possible to show no symptoms, most patients with P.A.D. will complain of weak legs, pain during ambulation, cold feet at bedtime, or have legs wounds which fail to heal despite treatment. Untreated P.A.D. conditions can lead to amputation. 

The Rio Grande Valley has an alarming rate of limb amputation associated with P.A.D. due to the high incidence of diabetes and obesity. Dr. Mego's patient-centered philosophy focuses on making all reasonable efforts to avoid limb amputation.

Dr. Mego says, "I am excited to open my facility which will focus on P.A.D. procedures. I will be able to deliver high-quality vascular care and get patients home the same day."

The Mission Vascular Center of Excellence specializes in treatments and interventions to restore blood flow to legs and feet. The center provides these treatments in an outpatient environment; most patients are cleared to go home in just a few hours.

An additional benefit of the Vascular Center of Excellence, patients typically pay significantly less money to have their procedure performed in an outpatient setting in comparison with a hospital.

"We are pleased to partner with Dr. Mego and his expert clinical team to provide a personalized care delivery model to the community," says Brooke Norris, the Director of Clinical Operations for Arise Vascular. "Our facility allows us to restore the quality of life to patients with P.A.D. through clinical and patient-centered care."

SOURCE Arise Vascular


These press releases may also interest you

at 08:16
On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the "Bonds"). Pursuant to the terms and...

at 08:07
On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA)...

at 08:05
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will...

at 08:05
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10,...

at 08:05
Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming...

at 08:05
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant...



News published on and distributed by: